VIDEX EC 250 MG
DIDANOSINE : 250 MG · DIN 02244598 · BRISTOL-MYERS SQUIBB CANADA
Health Canada status: CANCELLED POST MARKET
What is VIDEX EC?
VIDEX EC 250 MG contains DIDANOSINE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02244598, held by BRISTOL-MYERS SQUIBB CANADA, supplied as CAPSULE (ENTERIC-COATED) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Apr-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02244598 |
|---|---|
| Brand name | VIDEX EC |
| Generic / active ingredient | DIDANOSINE : 250 MG |
| Manufacturer | BRISTOL-MYERS SQUIBB CANADA |
| Strength | 250 MG |
| Dosage form | CAPSULE (ENTERIC-COATED) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AF02 DIDANOSINE |
| AHFS class | 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Apr-2020 |
| Original market date | 2002-01-02 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J05AF02 DIDANOSINE. 0 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VIDEX CHEWABLE DISPERSIBLE TAB 100MG | 100 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01940546 |
| VIDEX CHEWABLE DISPERSIBLE TAB 150MG | 150 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01940554 |
| VIDEX CHEWABLE DISPERSIBLE TAB 25MG | 25 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01940511 |
| VIDEX CHEWABLE DISPERSIBLE TAB 50MG | 50 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01940538 |
| VIDEX EC | 125 MG | CAPSULE (ENTERIC-COATED) | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 02244596 |
| VIDEX EC | 200 MG | CAPSULE (ENTERIC-COATED) | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 02244597 |
| VIDEX EC | 400 MG | CAPSULE (ENTERIC-COATED) | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 02244599 |
| VIDEX PEDIATRIC POWDER SOL 4G/BOTT | 4 G | POWDER FOR SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01940635 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.